Laboratorios Richmond SACIF Asset Resilience Ratio
Laboratorios Richmond SACIF asset resilience ratio. Laboratorios Richmond SACIF (RICH) has an Asset Resilience Ratio of 0.22% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Laboratorios Richmond SACIF defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Laboratorios Richmond SACIF (2011–2024)
Asset resilience ratio of Laboratorios Richmond SACIF from 2011 to 2024. This chart shows how Laboratorios Richmond SACIF's Asset Resilience Ratio has changed over time. Read how much debt does Laboratorios Richmond SACIF carry for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Laboratorios Richmond SACIF's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see RICH total asset value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AR$0.00 | 0% |
| Short-term Investments | AR$778.82 Million | 0.22% |
| Total Liquid Assets | AR$778.82 Million | 0.22% |
Asset Resilience Insights
- Limited Liquidity: Laboratorios Richmond SACIF maintains only 0.22% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Laboratorios Richmond SACIF Industry Peers by Asset Resilience Ratio
Compare Laboratorios Richmond SACIF's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Changchun High & New Technology Industries Group Inc
SHE:000661 |
Drug Manufacturers - Specialty & Generic | 5.50% |
|
Chengdu Kanghong Pharmaceuticals Group Co Ltd
SHE:002773 |
Drug Manufacturers - Specialty & Generic | 29.37% |
|
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267 |
Drug Manufacturers - Specialty & Generic | 0.01% |
|
Shenzhen Chipscreen Biosciences Co
SHG:688321 |
Drug Manufacturers - Specialty & Generic | 5.10% |
|
Cronos Group Inc
TO:CRON |
Drug Manufacturers - Specialty & Generic | 69.94% |
|
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557 |
Drug Manufacturers - Specialty & Generic | 0.29% |
|
HPGC Renmintongtai Pharmaceutical Corp
SHG:600829 |
Drug Manufacturers - Specialty & Generic | 0.00% |
Laboratorios Richmond SACIF Asset Resilience Ratio by Year (2011–2024)
Laboratorios Richmond SACIF asset resilience ratio by year from 2011 to 2024. The table below shows the annual Asset Resilience Ratio data for Laboratorios Richmond SACIF.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 1.13% | AR$2.95 Billion ≈ $2.13 Million |
AR$260.15 Billion ≈ $188.25 Million |
+1.01pp |
| 2023-12-31 | 0.12% | AR$404.16 Million ≈ $292.45K |
AR$337.32 Billion ≈ $244.09 Million |
-3.40pp |
| 2022-12-31 | 3.52% | AR$1.43 Billion ≈ $1.04 Million |
AR$40.72 Billion ≈ $29.47 Million |
-6.96pp |
| 2021-12-31 | 10.48% | AR$2.69 Billion ≈ $1.95 Million |
AR$25.69 Billion ≈ $18.59 Million |
+6.23pp |
| 2020-12-31 | 4.25% | AR$345.71 Million ≈ $250.16K |
AR$8.13 Billion ≈ $5.89 Million |
+4.22pp |
| 2019-12-31 | 0.03% | AR$1.72 Million ≈ $1.24K |
AR$5.13 Billion ≈ $3.72 Million |
+0.02pp |
| 2018-12-31 | 0.02% | AR$480.78K ≈ $347.90 |
AR$2.71 Billion ≈ $1.96 Million |
-0.15pp |
| 2017-12-31 | 0.16% | AR$2.56 Million ≈ $1.85K |
AR$1.55 Billion ≈ $1.12 Million |
-0.73pp |
| 2016-12-31 | 0.89% | AR$7.67 Million ≈ $5.55K |
AR$861.13 Million ≈ $623.12K |
+0.80pp |
| 2015-12-31 | 0.09% | AR$494.37K ≈ $357.73 |
AR$532.83 Million ≈ $385.56K |
-0.30pp |
| 2014-12-31 | 0.39% | AR$1.51 Million ≈ $1.09K |
AR$385.66 Million ≈ $279.06K |
-0.18pp |
| 2013-12-31 | 0.58% | AR$1.66 Million ≈ $1.20K |
AR$287.37 Million ≈ $207.94K |
-0.90pp |
| 2012-12-31 | 1.47% | AR$3.99 Million ≈ $2.89K |
AR$270.95 Million ≈ $196.06K |
+1.43pp |
| 2011-12-31 | 0.04% | AR$60.00K ≈ $43.42 |
AR$159.03 Million ≈ $115.07K |
-- |
About Laboratorios Richmond SACIF
Laboratorios Richmond S.A.C.I.F., a pharmaceutical company, develops and manufactures pharmaceutical products. It provides antiretroviral products for the treatment of human immunodeficiency virus (HIV); oncology and oncohematology drugs; cardiometabolic drugs, including antihypertensive, hypocholesterolemic, platelet antiaggregants, and hypoglycemic drugs; and neurological and psychiatric drugs … Read more